title: Innovative Therapeutics for Atrial Fibrillation: Imminent Breakthroughs or Much Ado About Nothing?
authors.affiliation: *Department of Medicine and Research Center, Montreal Heart Institute and Université de Montréal, Montreal, Quebec, Canada; †Department of Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada; and ‡Institute of Pharmacology, West German Heart and Vascular Center, University Duisburg-Essen, Essen, Germany.
authors.forename: Stanley
authors.initials: S
authors.lastname: Nattel
authors.forename: Dobromir
authors.initials: D
authors.lastname: Dobrev
mesh_terms: D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000925:Anticoagulants / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D017115:Catheter Ablation; D004059:Diffusion of Innovation; D055808:Drug Discovery / Q000639:trends*; D015507:Drugs, Investigational / Q000009:adverse effects / Q000627:therapeutic use*; D006329:Heart Conduction System / Q000187:drug effects* / Q000378:metabolism / Q000503:physiopathology; D006339:Heart Rate / Q000187:drug effects*; D006801:Humans; D026902:Potassium Channel Blockers / Q000627:therapeutic use; D015221:Potassium Channels / Q000187:drug effects / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects; D026941:Sodium Channel Blockers / Q000627:therapeutic use; D020521:Stroke / Q000175:diagnosis / Q000517:prevention & control
chemical_list: D000889:Anti-Arrhythmia Agents; D000925:Anticoagulants; D015507:Drugs, Investigational; D026902:Potassium Channel Blockers; D015221:Potassium Channels; D026941:Sodium Channel Blockers